Interest

Cardiff Oncology to Present at the Cowen 44th Annual Health Care Conference

Retrieved on: 
Monday, February 26, 2024

SAN DIEGO, Feb. 26, 2024 (GLOBE NEWSWIRE) -- Cardiff Oncology, Inc. (Nasdaq: CRDF), a clinical-stage biotechnology company leveraging PLK1 inhibition to develop novel therapies across a range of cancers, today announced that company management will participate in a fireside chat and 1x1 investor meetings at the Cowen 44th Annual Health Care Conference, which is taking place at the Marriott Copley Place in Boston from March 4-6, 2024.

Key Points: 
  • SAN DIEGO, Feb. 26, 2024 (GLOBE NEWSWIRE) -- Cardiff Oncology, Inc. (Nasdaq: CRDF), a clinical-stage biotechnology company leveraging PLK1 inhibition to develop novel therapies across a range of cancers, today announced that company management will participate in a fireside chat and 1x1 investor meetings at the Cowen 44th Annual Health Care Conference, which is taking place at the Marriott Copley Place in Boston from March 4-6, 2024.
  • Details of the fireside chat can be found below.
  • Interested parties can register for and access the live webcasts for these conferences by visiting the “ Events ” section of the Cardiff Oncology website.
  • The webcast replays will be available after the conclusion of the respective presentations.

Pliant Therapeutics to Participate in Upcoming Investor Conferences

Retrieved on: 
Monday, February 26, 2024

SOUTH SAN FRANCISCO, Calif., Feb. 26, 2024 (GLOBE NEWSWIRE) -- Pliant Therapeutics, Inc. (Nasdaq: PLRX), a clinical-stage biotechnology company and leader in the discovery and development of novel therapeutics for the treatment of fibrotic diseases, today announced participation in the following March investor conferences.

Key Points: 
  • SOUTH SAN FRANCISCO, Calif., Feb. 26, 2024 (GLOBE NEWSWIRE) -- Pliant Therapeutics, Inc. (Nasdaq: PLRX), a clinical-stage biotechnology company and leader in the discovery and development of novel therapeutics for the treatment of fibrotic diseases, today announced participation in the following March investor conferences.
  • Leerink Partners Global Biopharma Conference Keith Cummings, M.D., Pliant’s Chief Financial Officer, and Éric Lefebvre, M.D., Pliant’s Chief Medical Officer, will participate in a fireside chat on Tuesday, March 12, 2024, at 4:20 p.m. Eastern Time at the Fontainebleau Miami Beach Hotel in Miami, Florida.
  • Interested parties may access the live webcasts of the fireside chats by visiting the Investor Relations’ Events & Presentation page of Pliant’s website.
  • The webcast replays will be archived on the Pliant website for 30 days following the conclusion of the event.

Vicinity’s Software Defined Devices for 5G Advanced Private Networks at Mobile World Congress 2024

Retrieved on: 
Monday, February 26, 2024

BARCELONA, Spain, Feb. 26, 2024 (GLOBE NEWSWIRE) -- Vicinity Technologies Limited (Vicinity) is excited to announce that it will showcase a live demonstration of its latest 5G software-defined device at the Mobile World Congress 2024 in Barcelona, Spain, from February 26th to February 29th, 2024.

Key Points: 
  • BARCELONA, Spain, Feb. 26, 2024 (GLOBE NEWSWIRE) -- Vicinity Technologies Limited (Vicinity) is excited to announce that it will showcase a live demonstration of its latest 5G software-defined device at the Mobile World Congress 2024 in Barcelona, Spain, from February 26th to February 29th, 2024.
  • The Vicinity software-defined devices are powered by the NXP i.MX 8M Plus application processor and the NXP Layerscape 9130 baseband processor.
  • With their software-defined capabilities, Vicinity's 5G devices seamlessly integrate with any IoT application software embedded on the same device, enabling wireless connectivity and reducing costs.
  • Vicinity’s software defined devices will be showcased at Booth #7A9, located in Hall 7 at Great Britain & Northern Ireland Pavilion.

InspireSemi Announces Partial Conversion of Debentures

Retrieved on: 
Friday, February 23, 2024

The Company intends to issue an additional 359.50 PV Shares to the Converting Holders at a deemed issuance price of $19.00 per PV Share to settle in full $6,830.68 in interest owing (the "Interest Payment") to the Converting Holders as of the date of conversion being February 7, 2024.

Key Points: 
  • The Company intends to issue an additional 359.50 PV Shares to the Converting Holders at a deemed issuance price of $19.00 per PV Share to settle in full $6,830.68 in interest owing (the "Interest Payment") to the Converting Holders as of the date of conversion being February 7, 2024.
  • Therefore the issuance price of the PV Shares in respect of the Interest Payment is equivalent to Market Price of the SV Shares on February 23, 2024.
  • The issuance of the PV Shares in respect of the Interest Payment is subject to the approval of the TSX Venture Exchange.
  • All dollar amounts in this press release are expressed in Canadian dollars.

Sunrun Inc. Announces Pricing of Offering of $475 Million of Convertible Senior Notes

Retrieved on: 
Friday, February 23, 2024

The sale of the notes is expected to close on February 27, 2024, subject to customary closing conditions.

Key Points: 
  • The sale of the notes is expected to close on February 27, 2024, subject to customary closing conditions.
  • The notes will be senior, unsecured obligations of Sunrun.
  • The notes will be convertible into cash, shares of Sunrun’s common stock or a combination of cash and shares of Sunrun’s common stock, at Sunrun’s election.
  • If the initial purchasers exercise their option to purchase additional notes, Sunrun expects to enter into additional capped call transactions with the option counterparties.

Comscore to Announce Fourth Quarter 2023 Financial Results

Retrieved on: 
Friday, February 23, 2024

RESTON, Va., Feb. 23, 2024 (GLOBE NEWSWIRE) -- Comscore, Inc. (Nasdaq: SCOR), a trusted partner for planning, transacting and evaluating media, today announced that it plans to hold a conference call to discuss its financial results for the fourth quarter ended December 31, 2023 on Wednesday, March 6th at 5:00 p.m.

Key Points: 
  • RESTON, Va., Feb. 23, 2024 (GLOBE NEWSWIRE) -- Comscore, Inc. (Nasdaq: SCOR), a trusted partner for planning, transacting and evaluating media, today announced that it plans to hold a conference call to discuss its financial results for the fourth quarter ended December 31, 2023 on Wednesday, March 6th at 5:00 p.m.
  • Interested parties may access the conference call via live webcast at https://edge.media- server.com/mmc/p/z7odmktt, or participate via telephone by registering in advance at https://register.vevent.com/register/BIaa5cc4773d254d0caf9cc9fd04835b6a.
  • Upon registration, all telephone participants will receive the dial-in number along with a unique PIN number that can be used to access the call.
  • Following the conference call, a replay will be available via webcast at https://ir.comscore.com/events-presentations.

Amplify Energy Schedules Fourth Quarter 2023 Earnings Release and Conference Call

Retrieved on: 
Thursday, February 22, 2024

Jim Frew -- SVP & Chief Financial Officer(832) [email protected]

Key Points: 
  • HOUSTON, Feb. 22, 2024 (GLOBE NEWSWIRE) -- Amplify Energy Corp. (“Amplify” or the “Company”) (NYSE: AMPY) announced today that it will report fourth quarter 2023 financial and operating results after the U.S. financial markets close on March 6, 2024.
  • Management will host a conference call at 10:00 a.m. CT on March 7, 2024 to discuss the Company’s results.
  • Interested parties are invited to participate in the conference call by dialing (800) 343-5172 (Conference ID: AEC4Q23) at least 15 minutes prior to the start of the call.
  • A replay of the call will be available by phone at (800) 654-1563 (Access Code: 28240256) for a fourteen-day period following the call.

TPI Composites, Inc. Announces Fourth Quarter and Full Year 2023 Earnings Results; Enhanced Liquidity Position and Projects Improved Profitability for the Second Half of 2024

Retrieved on: 
Thursday, February 22, 2024

Number of wind blade manufacturing lines that are dedicated to our customers under long-term supply agreements at the end of the period.

Key Points: 
  • Number of wind blade manufacturing lines that are dedicated to our customers under long-term supply agreements at the end of the period.
  • Number of wind blade manufacturing lines installed and either in operation, startup or transition during the period.
  • Net cash used in operating activities for the year ended December 31, 2023, was $81.0 million compared to $62.3 million in 2022.
  • Capital expenditures were $36.1 million for the year ended December 31, 2023, as compared to $18.8 million in 2022.

Dorchester Minerals, L.P. Announces 2023 Results

Retrieved on: 
Thursday, February 22, 2024

The Partnership’s independent engineering consultant estimated its total proved oil and natural gas reserves to be 83.3 billion cubic feet of natural gas equivalents (bcfe) as of December 31, 2023.

Key Points: 
  • The Partnership’s independent engineering consultant estimated its total proved oil and natural gas reserves to be 83.3 billion cubic feet of natural gas equivalents (bcfe) as of December 31, 2023.
  • Approximately 82% of these reserves are attributable to the Partnership’s Royalty Properties and 18% are attributable to its Net Profits Interest.
  • Natural gas accounted for 40% of proved reserves as of December 31, 2023, all of which were classified as proved developed producing.
  • The Partnership distributed a total of $137.5 million to its common unitholders from May 2023 through February 2024 attributable to 2023 activity.

Adaptive Biotechnologies to Present at the TD Cowen 44th Annual Healthcare Conference

Retrieved on: 
Thursday, February 22, 2024

SEATTLE, Feb. 22, 2024 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation (Nasdaq: ADPT), a commercial stage biotechnology company that aims to translate the genetics of the adaptive immune system into clinical products to diagnose and treat disease, today announced it will be participating in the upcoming TD Cowen 44th Annual Healthcare Conference in Boston, MA.

Key Points: 
  • SEATTLE, Feb. 22, 2024 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation (Nasdaq: ADPT), a commercial stage biotechnology company that aims to translate the genetics of the adaptive immune system into clinical products to diagnose and treat disease, today announced it will be participating in the upcoming TD Cowen 44th Annual Healthcare Conference in Boston, MA.
  • Adaptive Biotechnologies’ management is scheduled to present on Monday, March 4th at 11:10 a.m. Pacific Time / 2:10 p.m. Eastern Time.
  • Interested parties may access a live and archived webcast of the presentation on the “Investors” section of the company website at: www.adaptivebiotech.com .